We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clinical correlates of the observed immunological modifications.
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study / Capasso, Nicola; Palladino, Raffaele; Cerbone, Vincenza; Spiezia, Antonio Luca; Covelli, Bianca; Fiore, Antonia; Lanzillo, Roberta; Carotenuto, Antonio; Petracca, Maria; Stanziola, Lucia; Scalia, Giulia; Brescia Morra, Vincenzo; Moccia, Marcello. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - (2022). [10.1007/s00415-022-11350-1]
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
Petracca, Maria;
2022
Abstract
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with pre-infusion assessment; (2) over the course of treatment; and (3) possible clinical correlates of the observed immunological modifications.| File | Dimensione | Formato | |
|---|---|---|---|
|
s00415-022-11350-1.pdf
accesso aperto
Note: Capasso_Ocrelizumab effect_2022
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.03 MB
Formato
Adobe PDF
|
1.03 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
